The proportion of tumor-infiltrating myeloid-derived immune suppressor cells (MDSCs) and B lymphocytes increases in the TME over time, and these cells, through the secretion of interleukin 23 (IL-23), drive PCa progression to castration-resistant prostate cancer (CRPC) (Ammirante et al., 2010; Calcinotto et al., 2018). This evidence concerns the gene IL37 and neoplasm.